Scancell Holdings plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCNLF research report →
Companywww.scancell.co.uk
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens.
- CEO
- Phillip John L'Huillier
- IPO
- 2013
- Employees
- 61
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $314.45M
- P/E
- -38.59
- P/S
- 45.16
- P/B
- -25.40
- EV/EBITDA
- -39.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 78.45%
- Op Margin
- -283.34%
- Net Margin
- -116.98%
- ROE
- 90.29%
- ROIC
- -113.84%
Growth & Income
- Revenue
- $4.71M · -10.62%
- Net Income
- $-12,272,000 · -2.82%
- EPS
- $-0.01 · -85.29%
- Op Income
- $-15,001,000
- FCF YoY
- 59.51%
Performance & Tape
- 52W High
- $0.31
- 52W Low
- $0.12
- 50D MA
- $0.17
- 200D MA
- $0.15
- Beta
- 0.57
- Avg Volume
- 6.46K
Get TickerSpark's AI analysis on SCNLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SCNLF Coverage
We haven't published any research on SCNLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SCNLF Report →